Neurogene Q1 net loss $16.9M; NGN-401 safety positive, on track for efficacy data 4Q24

Neurogene Inc.

2024-Q1 EPS reported -$1.00

Cash and investments $169.5M as of March 31, 2024; cash runway into 2H 2026.
R&D expenses $13.5M (up 31% YoY); net loss $16.9M vs $12.3M in Q1 2023.
NGN-401 gene therapy for Rett syndrome well-tolerated; all AEs mild/Grade 1.
Australian regulatory clearance received; interim efficacy data from Cohort 1 expected 4Q 2024.
Advancing early-stage pipeline; another product candidate expected to enter clinic in 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Neurogene Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 10, 2024, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2024.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Neurogene Inc. filing history →

Source: SEC EDGAR

accession 0001404644-24-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.